The potential use of therapeutics and prophylactic mRNA vaccines in human papillomavirus (HPV)
- Title
- The potential use of therapeutics and prophylactic mRNA vaccines in human papillomavirus (HPV)
- Abstract
- Cervical cancer (CC) and other malignant malignancies are acknowledged to be primarily caused by persistent human papillomavirus (HPV) infection. Historically, vaccinations against viruses that produce neutralizing antibodies unique to the virus have been an affordable way to manage viral diseases. CC risk is decreased, but not eliminated, by HPV vaccinations. Since vaccinations have been made available globally, almost 90% of HPV infections have been successfully avoided. On the lesions and diseases that are already present, however, no discernible treatment benefit has been shown. As a result, therapeutic vaccines that elicit immune responses mediated by cells are necessary for the treatment of established infections and cancers. mRNA vaccines possess remarkable potential in combating viral diseases and malignancy as a result of their superior industrial production, safety, and efficacy. Furthermore, considering the expeditiousness of production, the mRNA vaccine exhibits promise as a therapeutic approach targeting HPV. Given that the HPV-encoded early proteins, including oncoproteins E6 and E7, are consistently present in HPV-related cancers and pre-cancerous lesions and have crucial functions in the progression and persistence of HPV-related diseases, they serve as ideal targets for therapeutic HPV vaccines. The action mechanism of HPV and HPV-related cancer mRNA vaccines, their recent advancements in clinical trials, and the potential for their therapeutic applications are highlighted in this study, which also offers a quick summary of the present state of mRNA vaccines. Lastly, we highlight a few difficulties with mRNA HPV vaccination clinical practice and provide our thoughts on further advancements in this quickly changing sector. It is expected that mRNA vaccines will soon be produced quickly for clinical HPV prevention and treatment.
- Scientific Type
- غير معروف
- Journal volume
- Volume21,Issue1
- Collaboration type
- مشترك
- Publish Date
- May 31, 2024
- Participated Universities (Publication)
-
Alnoor University
- Scopus status
- In Scopus
- Scopus index year
- 2 024
- Scopus quarter
- 1
- Scopus citation score
- 5.5
- Clarivate status
- In Clarivate
- Clarivate index year
- 2 024
- Clarivate impafact
- 5.900000095
- Pub. Med. status
- In PubMed
- Author (Publication)
-
عمر قتيبة بدر الدين محمود
- Journal (Publication)
- Virology journal
- Publisher (Publication)
- BioMed Central Ltd
- ISSN
- 1743-422X
- Country (Publication)
-
United kingdom
- Country type
- عالمية
- College (Publication)
-
College of Pharmacy
- Departement (Publication)
-
Department of Pharmacy
Part of The potential use of therapeutics and prophylactic mRNA vaccines in human papillomavirus (HPV)